Analgesic Solutions

7 articles about Analgesic Solutions

• Food and Drug Administration (FDA) Approval of GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences' EPIDIOLEX® (cannabidiol) CV Marks First Drug Approval and Scheduling Decision Supported by Analgesic Solutions' MADDERS® System

  10/22/2018

  Drug Enforcement Agency (DEA) Places FDA-Approved Drug Containing CBD in Schedule V

• Analgesic Solutions Presenting MADDERS® System at the Advancements and Challenges in Abuse Potential Evaluation Meeting

  10/10/2018

  Dr. Ryan Lanier, Ph.D., Associate Director, Consulting Unit at Analgesic Solutions will present "A Systematic Approach to Monitor Misuse, Abuse and Diversion in Clinical Trials (MADDERS)" at the Advancements and Challenges in Abuse Potential Evaluation Meeting on Thursday October 11th in Bethesda, MD.

• Analgesic Solutions Pain Research Methodology Applicable Across Therapeutic Spectrum

  6/25/2018

  Keynote Speaker at Drug Information Association Meeting Emphasizes the Need for Better Pain Research

• Analgesic Solutions Presents Data from the Implementation of its Misuse, Abuse, and Diversion Drug Event Reporting System (MADDERS®)

  6/13/2018

  Company Establishes Scientific Advisory Board for the MADDERS

• Jacqueline Delfgaauw, Ph.D. Joins Analgesic Solutions as Executive Director, Clinical Science

  1/3/2018

  Dr. Delfgaauw's extensive experience in the clinical development of various products focused in pain will be a critical to Analgesic Solutions' ongoing success and rapid expansion going forward.

• Analgesic Solutions Presents Data On The Use Of MADDERS To Assess Potentially Abuse-Related Events In Clinical Trials At The 79th Annual Scientific Meeting Of The College On Problems Of Drug Dependence

  6/19/2017

• Analgesic Solutions Announces Presentation Of Signature Quantitative Data Surveillance System

  10/3/2016